Human Umbilical Cord–Derived Mesenchymal Stem Cells in the Treatment of Multiple Sclerosis Patients: Phase I/II Dose-Finding Clinical Study
Fatima Jamali(University of Jordan), Abdalla Awidi(University of Jordan), Bayan Hourani(University of Jordan), Said Dahbour(University of Jordan), Reem Rahmeh(University of Jordan), Dana Alhattab(King Abdullah University of Science and Technology), Mona R. Hassuneh(University of Jordan), Hisham Bawaneh(Jordan Hospital), Ali Al‐Radaideh(Qatar University), Mayis Aldughmi(University of Jordan), Hind Khwaireh(University of Jordan), Serin Atiani(Princess Sumaya University for Technology), Kawthar Abu Moshref(University of Jordan), Joud Al- Jaghbeer(University of Jordan), Sally Arafat(University of Jordan), Osameh Ababneh(University of Jordan), Alia A. Alghwiri(University of Jordan)
Cited by 25
Related Papers
siRNA: Mechanism of action, challenges, and therapeutic approaches
|European Journal of Pharmacology|2021|428
Intra-articular injection of expanded autologous bone marrow mesenchymal cells in moderate and severe knee osteoarthritis is safe: a phase I/II study
|Journal of Orthopaedic Surgery and Research|2017|141
Mesenchymal stem cells and conditioned media in the treatment of multiple sclerosis patients: Clinical, ophthalmological and radiological assessments of safety and efficacy
|CNS Neuroscience & Therapeutics|2017|123